It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol Hill purple at the 2026 National Lupus Advocacy Summit this April!

Galapagos (NASDAQ:GLPG) executives used the company’s year-end 2025 financial results call to outline a strategic reset ...

Moby summary of Aurinia Pharmaceuticals Inc.'s Q4 2025 earnings call ...

Dr. Dolsten, former Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer, brings leadership experience spanning approximately 50 regulatory approvals and ...

Galapagos NV (GLPG) reported FY25 GAAP EPS of €4.87 and €1.11B revenue, driven by one-time accounting from Gilead ...

(CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior ...

Cullinan Therapeutics has a robust T-cell engager pipeline, savvy management, and a strong cash position. Read more on what investors should know about the company.

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as ...

Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.

A woman in her 40s presented with progressive cognitive decline, expressive language difficulty and episodic confusion. Her initial symptoms were misattributed to psychiatric illness, and later to ...

Social determinants of health were associated with increased risks for organ damage and mortality among patients with lupus.